Core Insights - Junshi Biosciences is a leading biopharmaceutical company focused on innovation, with a mission to provide world-class, trustworthy innovative drugs to patients globally [1] - The company has developed over 50 innovative drugs, with 5 products already launched in domestic and international markets, including the first domestically developed PD-1 inhibitor, Toripalimab [1] Group 1: Digital Transformation and Innovation - The company has implemented a digital control system at its Shanghai Lingang production base, which is recognized as a model for modern biopharmaceutical industrialization [1] - The project includes the establishment of an Electronic Batch Record (EBR) system, which automates data collection and enhances compliance, efficiency, and supply chain stability [1] - The system features 1780 standardized operational steps and 4380 monitoring points for anomalies, significantly improving the efficiency of batch record review and release [1] Group 2: Industry Impact and Future Directions - The project serves as a replicable and promotable model for digital transformation in the biopharmaceutical industry [2] - Junshi Biosciences aims to continue deepening its digital and intelligent transformation to enhance production efficiency and product quality, ultimately providing safer and more accessible innovative drugs to global patients [2]